



Press release 200-09-06

MEDIVIR REINFORCES MANAGEMENT GROUP

Stefan Mårtensson has been appointed Vice President Sales & Marketing, a newly created position with responsibility for the establishment and operation of Medivir's future regional sales and marketing organization. He commences in October 2007 and will belong to the Medivir management team.

Medivir presently has one project in phase III clinical trials (Lipsovir[®]), three projects in phase II and three in phase I. Medivir has operational responsibility for two of these projects - Lipsovir[®] and MIV-701 - while collaborating partners are responsible for the others. Medivir has retained the regional marketing rights for all of these projects. Existing and future collaboration agreements with other companies can provide additional opportunities for sales and marketing of further pharmaceuticals in the regional market.

Stefan Mårtensson has a masters degree in economics and has had senior positions within marketing, sales and business development with global pharmaceutical companies such as GlaxoSmithKline and Novartis over the last 20 years. Stefan comes most recently from a position as Head of Marketing at Novartis Sverige AB.

"Stefan's long experience of the Nordic pharmaceutical markets and his widespread contact net within the global pharmaceutical industry will make him extremely valuable in the task of building and operating Medivir's future sales and marketing organization", says Medivir's CEO Lars Adlersson.

For additional information, please contact

Rein Piir, CFO & VP, Investor Relations, at Medivir +46 8 5468 3123 or
+46 708 5327 292.

For further information on Medivir, please see our website: www.medivir.se